Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Equillium, Inc.
Equillium, Inc. News
Equillium, Inc. Quantitative Score
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Equillium, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Equillium, Inc. Financials
Table Compare
Compare EQ metrics with: | |||
|---|---|---|---|
Earnings & Growth | EQ | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | EQ | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | EQ | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | EQ | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Equillium, Inc. Income
Equillium, Inc. Balance Sheet
Equillium, Inc. Cash Flow
Equillium, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Equillium, Inc. Executives
| Name | Role |
|---|---|
| Mr. Bruce D. Steel C.F.A. | Co-Founder, Chief Executive Officer & Director |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & President |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President & Chief Operating Officer |
| Ms. Penny Tom | Senior Vice President of Finance & Principal Accounting Officer |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Bruce D. Steel C.F.A. | Co-Founder, Chief Executive Officer & Director | Male | 1966 | 471.34K |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & President | 1981 | 428.49K | |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President & Chief Operating Officer | Female | 1970 | 415.3K |
| Ms. Penny Tom | Senior Vice President of Finance & Principal Accounting Officer | Female | -- | |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications | Male | -- |
Equillium, Inc. Insider Trades
| Date | 25 Nov |
| Name | Zedelmayer Christine |
| Role | Sr. Vice President and COO |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 100 |
| Date | 25 Nov |
| Name | Zedelmayer Christine |
| Role | Sr. Vice President and COO |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 7998 |
| Date | 29 Aug |
| Name | Connelly Stephen |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1025000 |
| Date | 29 Aug |
| Name | Tom Penny |
| Role | Principal Accounting Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 525000 |
| Date | 29 Aug |
| Name | Zedelmayer Christine |
| Role | Sr. Vice President and COO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 725000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 25 Nov | Zedelmayer Christine | Sr. Vice President and COO | Disposed | S-Sale | 100 |
| 25 Nov | Zedelmayer Christine | Sr. Vice President and COO | Disposed | S-Sale | 7998 |
| 29 Aug | Connelly Stephen | Chief Scientific Officer | Acquired | A-Award | 1025000 |
| 29 Aug | Tom Penny | Principal Accounting Officer | Acquired | A-Award | 525000 |
| 29 Aug | Zedelmayer Christine | Sr. Vice President and COO | Acquired | A-Award | 725000 |